Truist Securities Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $62
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $62.
Truist Securities analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $62.